2 results
Approved WMOPending
Primary ObjectiveTo assess the efficacy of furmonertinib compared to platinum-based chemotherapy using progression-free survival (PFS) in previously untreated patients with locally advanced or metastatic non-squamous NSCLC with EGFR exon 20…
Approved WMORecruiting
DOSE EXPLORATION:Primary:To determine the safety and tolerability of GSK2857916 in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each sub-study combination treatment.Secondary:…